Evidence map›Paper›PMID 31069565›Full record

ArticleClinical & experimental metastasis2019

Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome.

Mithalesh Kumar Singh, Lata Singh, Neelam Pushker, Neeru Saini, Rachna Meel, Kunzang Chosdol, Sameer Bakhshi, Seema Sen, Pradeep Venkatesh, Bhavna Chawla and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mithalesh Kumar SinghDepartment of Ocular Pathology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Lata SinghDepartrment of Biosciences, Jamia Millia Islamia, New Delhi, India.
Neelam PushkerDepartment of Ophthalmology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Neeru SainiFunctional Genomics Unit, Institute of Genomics and Integrative Biology, New Delhi, India.
Rachna MeelDepartment of Ophthalmology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Kunzang ChosdolDepartment of Biochemistry, AIIMS, New Delhi, India.
Sameer BakhshiDepartment of Medical Oncology, IRCH, AIIMS, New Delhi, India.
Seema SenDepartment of Ocular Pathology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Pradeep VenkateshDepartment of Ophthalmology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Bhavna ChawlaDepartment of Ophthalmology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Jasbir KaurDepartment of Ocular Biochemistry, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Seema KashyapDepartment of Ocular Pathology, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. dr_skashyap@hotmail.com.ORCID 0000-0002-8746-9017
All India Institute of Medical Sciences · INAll India Institute of Medical Sciences Raipur · INInstitute of Genomics and Integrative Biology · INJamia Millia Islamia · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation in uveal melanoma (UM) is linked to a bad prognosis. It is rare type of cancer, of which the metastases are usually fatal within a year. Infiltration with an inflammatory infiltrate increases with disease progression but does not seem to inhibit metastasis. The Canonical NFκB (C-NFκB) pathway is known to play a crucial role in tumor inflammation. We therefore, studied the expression of canonical NFκB proteins and their prognostic relevance in UM. Our study evaluated the expression of C-NFκB proteins (p65, p50, and c-Rel) by using immunohistochemistry on sections from 75 formalin-fixed UM. Activation of the NFκB subunit was determined on fresh tumor specimens by measuring the DNA-binding activity in nuclei using an NFκB ELISA assay. Real-time PCR was performed on frozen material on 58 tumors. The presence of native C-NFκB heterodimers (p65/p50 and c-Rel/p50) was confirmed by co-immunoprecipitation followed by Western blotting. We observed a high nuclear immunoreactivity of p65, p50, and c-Rel proteins in 54, 60 and 41% UM cases, respectively. Expression of C-NFκB proteins significantly correlated with parameters which are related to the inflammatory environment of UM. Nuclear immunoreactivity of p65 and p50 was associated with lower patient survival (p = 0.041; p = 0.048) while c-Rel was not. Our finding reveals that C-NFκB proteins expressed are more often in UM with inflammation than those without inflammation. Activation of the canonical NFκB pathway is more frequent in high risk UM patients. These observations might help to understand the behaviour of high risk tumors, with upregulation of C-NFκB proteins contributing to tumor aggressiveness.

Indexed as

DNA-Binding ProteinsHumansMelanocytesMelanomaNF-kappa B p50 SubunitProto-Oncogene Proteins c-relTranscription Factor RelAUveaUveal MelanomaUveal NeoplasmsDNA-Binding ProteinsNF-kappa B p50 SubunitProto-Oncogene Proteins c-relRELA protein, humanREL protein, humanTranscription Factor RelAc-Rel/p50 heterodimerImmunohistochemistryInflammationNFκBp65/p50Uveal melanoma

Identifiers

PMID31069565
OpenAlexW2943917888

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.